This week in transparency news: February 16 – February 22, 2019

by Staff writer,
Posted on 2/22/2019

Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:

New user experience survey launched –ClinicalTrials.gov

To improve user experience, ClinicalTrials.gov has launched an online survey to learn about the typical visitor’s background knowledge in clinical trials. The registry seeks to enhance the Learn About Clinical Studies page. Health Literacy Media (HLM), a Missouri-based nonprofit organization with health literacy expertise, is providing assistance in launching this survey.

Catch up on all ClinicalTrials.gov news here

EMA implored to improve trial reporting, with over 50% of trials still missing results Outsourcing Pharma

According to a report by TranspariMED and Health Action International, more than half of due clinical trials are missing results on the EU clinical trials register (EUCTR). The report found that universities failed to post more than 80% of clinical trial results.

Read the full article by Melissa Fassbender

Major medical journals don’t follow their own rules for reporting results from clinical trialsScience Mag

The Centre for Evidence-Based Medicine Outcome Monitoring Project (COMPare) discovered that only 13% of studies reported outcomes correctly. Many researchers didn’t correctly report the primary outcomes they set out to measure, didn’t report all the secondary outcomes, and added new outcomes. The COMpare team looked at studies published over a six-week period in five leading medical journals.

Read more about COMPare’s findings via Jocelyn Kaiser

European Medicines Agency forced to pay London leasePharma Times

The European Medicines Agency (EMA) lost a high court case to cancel its £500 million long-term office lease in London. Canary Wharf group, the landlord, won the right to enforce the lease, which lasts until 2039. The EMA has recently relocated to Amsterdam in the wake of Brexit.

Anna Smith has the full story in Pharma Times

Share: